## A TIMELINE OF

OPIOID SUBSTITUTION (AGONIST)
TREATMENT

IN BRITISH COLUMBIA

Rolleston Report released (United Kingdom): Elite committee of British physicians recognizes opiate addiction as 1926 a "manifestation of disease" and that continued administration of opiates by physicians can reduce the morbidity associated with addiction 1939 Methadone is first synthesized (Germany) Methadone treatment was first dispensed in Vancouver by the Narcotic Addiction Foundation of British Columbia for 1959 brief detoxification Methadone treatment officially introduced in Canada: run by the Addiction Research Foundation in Ontario, they also 1964 developed guidelines for "good medical practice" in opiate maintenance treatment for the country **Late 1960s** Methadone Maintenance Treatment (MMT) programs become well established across Canada including BC. Amendments to the Narcotic Control Act place strict regulations on the prescription of methadone in Canada: All 1972 physicians prescribing methadone require authorization from federal health authorities Number of patients in MMT drops to 560 in Canada: This represents about a third of the patients 1982 registered in 1972, approximately half of whom were registered in BC 1991 Number of patients registered in Methadone Maintenance Treatment (MMT) program in BC is 1,221 Federal authorities pass jurisdiction over MMT to Provincial authorities nationwide. The College of Physicians and 1996 Surgeons of BC (CPSBC) takes over management of the Province's MMT program. Number of patients registered in MMT program in BC is 8,221: Rapid rise in number of patients in MMT occurs after 2004 CPSBC loosens regulations on physician prescribing 2005 North American Opiate Medication Initiative (NAOMI) trial begins 2009 Number of patients registered in MMT programs in BC is 11,033 Results of the NAOMI study are published in the New England Journal of Medicine (NEJM) Results indicate that participants treated with diacetylmorphine (heroin) reported improved physical and mental health, were more likely to remain in treatment and were less likely to take illicit drugs 2010 Buprenorphine/naloxone (Suboxone) approved as a limited coverage benefit in Pharmacare BC College of Pharmacists requires all pharmacist and pharmacist managers to complete MMT training by September 30, 2011 to ensure compliance with the Board approved policies. Once complete pharmacists are required to sign the 2011 Declaration of Completion and Understanding form. Number of patients registered in MMT programs in BC is 13,046 2013 BC Methadone Maintenance System Report published outlining performance measures for 2011/2012 2014 All methadone patients in BC switched to a more concentrated formulation of methadone "Methadose". Many patients reported concerns about Methadose, including that it did not last 24 hours 2015 BC Methadone Maintenance System Report published outlining performance measures for 2013/2014 Reports shows that only 36% of people who started on methadone maintenance treatment (MMT) in 2012/2013 were retained on MMT after 12 months. Prescribers no longer require an exemption to prescribe Suboxone for opioid use disorder 2016 The College of Physicians and Surgeons will no longer maintain a central registry of patients registered in the methadone program. First results of the SALOME trial are published in Journal of the American Medical Association (JAMA): Psychiatry Apr '16 Results indicate that hydromorphone is as effective as diacetylmorphine (heroin) in treating individuals with severe opioid use disorder. Physicians in British Columbia no longer have to hold a federal Section 56 exemption from the Controlled Drugs and Jul '16 Substances Act in order to prescribe buprenorphine/naloxone. See statement. Handbook for patients on opioid substitution treatment developed by patients with financial support from BC Ministry of Health and coordination by the Centre for Addictions Research of British Columbia. Patients helping patients 2017 understand opioid substitution treatment. PharmaCare covers Methadose™, buprenorphine/naloxone, and Kadian® 24-hour slow-release oral morphine for opioid use Feb '17 disorder treatment under Plan G, based on income assessment and clinical criteria The British Columbia Center on Substance Use (BCCSU) became responsible for the education and training pathways Jun '17 and clinical care guidelines for prescribers of opioid use disorder treatment in BC **Jul** '17 Updated BC Centre on Substance Use Guideline for the clinical management of opioid use disorder published • The updated guidelines recommend Buprenorphine/Naloxone (Suboxone) as the preferred first-line opioid agonist treatment for opioid use disorder. Slow or sustained release oral morphine recommended as an alternative oral treatment to methadone and/or burprenorphine/naloxone. BCCSU Guidance for Injectable Opioid Agonist Treatment (iOAT) for Opioid Use Disorder released. Oct '17 2018 Amendments to Professional Practice Policy - 66: College of Pharmacists of BC, come into effect. Name changed from "Methadone Maintenance Treatment" to "Opioid Agonist Treatment" Includes policy guides for Buprenorphine/naloxone and slow release oral morphine maintenance treatment OAT prescribing is added to the scope of nurse practitioners Feb '18 Federal Government announces regulatory changes to allow health practitioners to prescribe and administer Mar '18 Methadone without an exemption Federal government also announces plans to change regulations surrounding the prescription of diacetylmorphine (Heroin) outside of a hospital setting. Metadol-D made available via Special Authority Request Sep '18

New <u>online training</u> is developed by the BC Pharmacy Association for OAT for pharmacists

Metadol-D <u>becomes eligible</u> for regular health benefit coverage through PharmaCare

Dec '18

2019

found at https://towardtheheart.com/